<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Pediatr Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">J Pediatr Genet</journal-id>
<journal-id journal-id-type="doi">10.1055/s-00029027</journal-id>
<journal-title-group>
<journal-title>Journal of Pediatric Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">2146-4596</issn>
<issn pub-type="epub">2146-460X</issn>
<publisher>
<publisher-name>Georg Thieme Verlag KG</publisher-name>
<publisher-loc>Stuttgart · New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28794907</article-id>
<article-id pub-id-type="pmc">5548529</article-id>
<article-id pub-id-type="doi">10.1055/s-0037-1599147</article-id>
<article-id pub-id-type="publisher-id">1600030</article-id>
<article-categories>
<subj-group>
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>RAI1</italic>
Overexpression Promotes Altered Circadian Gene Expression and Dyssomnia in Potocki–Lupski Syndrome
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mullegama</surname>
<given-names>Sureni V.</given-names>
</name>
<xref ref-type="aff" rid="AF1600030-1">1</xref>
<xref ref-type="aff" rid="AF1600030-2">2</xref>
<xref ref-type="fn" rid="FN1600030-5">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alaimo</surname>
<given-names>Joseph T.</given-names>
</name>
<xref ref-type="aff" rid="AF1600030-1">1</xref>
<xref ref-type="fn" rid="FN1600030-5">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fountain</surname>
<given-names>Michael D.</given-names>
</name>
<xref ref-type="aff" rid="AF1600030-1">1</xref>
<xref ref-type="fn" rid="FN1600030-5">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Burns</surname>
<given-names>Brooke</given-names>
</name>
<xref ref-type="aff" rid="AF1600030-3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Balog</surname>
<given-names>Amanda Hebert</given-names>
</name>
<xref ref-type="aff" rid="AF1600030-3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Li</given-names>
</name>
<xref ref-type="aff" rid="AF1600030-1">1</xref>
<xref ref-type="aff" rid="AF1600030-4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elsea</surname>
<given-names>Sarah H.</given-names>
</name>
<xref ref-type="aff" rid="AF1600030-1">1</xref>
<xref ref-type="aff" rid="AF1600030-2">2</xref>
<xref ref-type="aff" rid="AF1600030-3">3</xref>
<xref ref-type="author-notes" rid="CO1600030-1"></xref>
</contrib>
</contrib-group>
<aff id="AF1600030-1">
<label>1</label>
<institution>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, United States</institution>
</aff>
<aff id="AF1600030-2">
<label>2</label>
<institution>Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California, United States</institution>
</aff>
<aff id="AF1600030-3">
<label>3</label>
<institution>Department of Human and Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia, United States</institution>
</aff>
<aff id="AF1600030-4">
<label>4</label>
<institution>Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China</institution>
</aff>
<author-notes>
<corresp id="CO1600030-1"><bold>Address for correspondence </bold>Sarah H. Elsea, PhD, FACMG <institution>Department of Molecular and Human Genetics, Baylor College of Medicine</institution><addr-line>One Baylor Plaza, NAB2015, Houston, TX 77030</addr-line><country>United States</country><email>elsea@bcm.edu</email></corresp>
<fn fn-type="conflict" id="d30e182">
<p><bold>Conflict of Interest</bold> None.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>3</month>
<year>2017</year>
</pub-date>
<volume>6</volume>
<issue>3</issue>
<fpage>155</fpage>
<lpage>164</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>11</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>1</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© Thieme Medical Publishers</copyright-statement>
</permissions>
<abstract>
<p>
<italic>Retinoic acid induced 1</italic>
(
<italic>RAI1</italic>
) encodes a dosage-sensitive gene that when haploinsufficient results in Smith–Magenis syndrome (SMS) and when overexpressed results in Potocki–Lupski syndrome (PTLS). Phenotypic and molecular evidence illustrates that haploinsufficiency of
<italic>RAI1</italic>
disrupts circadian rhythm through the dysregulation of the master circadian regulator,
<italic>circadian locomotor output cycles kaput</italic>
(
<italic>CLOCK)</italic>
, and other core circadian components, contributing to prominent sleep disturbances in SMS. However, the phenotypic and molecular characterization of sleep features in PTLS has not been elucidated. Using the Pittsburgh Sleep Quality Index (PSQI), caregivers of 15 school-aged children with PTLS reported difficulties in initiating sleep. Indeed, more than 70% of individuals manifested moderate to severe sleep latency, as defined by the PSQI. Moreover, these individuals manifested difficulties in sleep maintenance, with middle of the night and early morning awakenings. When assessing daytime sleepiness through the Epworth Sleepiness Scale, approximately 21% of the individuals manifested excessive daytime somnolence. This indicates that mild dyssomnia characterizes the majority of the sleep phenotype, with occasionally problematic daytime somnolence, a phenotype different than that expressed by individuals with SMS, where daytime sleepiness is a chronic problem. Gene expression analysis of the core circadian machinery in the hypothalamus of the PTLS mouse model (
<italic>Rai1</italic>
-Tg) found significant dysregulation of the transcriptional activators,
<italic>Clock</italic>
and
<italic>Arntl</italic>
, and the transcriptional repressors,
<italic>Per1–3</italic>
and
<italic>Cry1/2</italic>
, during both light and dark phases. These findings suggest a partial loss of circadian entrainment typically evoked by environmental photic cues. Examination of circadian clock gene expression in the
<italic>Rai1-</italic>
Tg mouse heart, liver, and kidney found unchanged expression of
<italic>Clock</italic>
and most of its downstream targets during both light and dark phases, suggesting an asynchronized circadian rhythm. Furthermore, examination of circadian gene expression in synchronized PTLS lymphoblasts revealed reduced transcripts of the Period (
<italic>PER1–3</italic>
) family and normal expression of
<italic>CRY1/2</italic>
. The finding that central circadian gene expression was altered while many peripheral circadian components were intact suggests a tissue-specific circadian uncoupling of the circadian machinery due to
<italic>Rai1</italic>
overexpression. Overall, our results demonstrate that overexpression of
<italic>RAI1</italic>
results in sleep deficiencies in individuals with PTLS due to a lack of properly regulated circadian machinery gene expression and highlight the importance of evaluating sleep concerns in individuals with PTLS.
</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Potocki–Lupski syndrome</kwd>
<kwd>RAI1</kwd>
<kwd>circadian rhythm</kwd>
<kwd>sleep disturbance</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>